Catalyzes the hydrolysis of GTP and utilizes this energy to mediate vesicle scission at plasma membrane during endocytosis and filament remodeling at many actin structures during organization of the actin cytoskeleton (PubMed:15731758, PubMed:19605363, PubMed:19623537, PubMed:33713620, PubMed:34744632). Plays an important role in vesicular trafficking processes, namely clathrin-mediated endocytosis (CME), exocytic and clathrin-coated vesicle from the trans-Golgi network, and PDGF stimulated macropinocytosis (PubMed:15731758, PubMed:19623537, PubMed:33713620). During vesicular trafficking process, associates to the membrane, through lipid binding, and self-assembles into ring-like structure through oligomerization to form a helical polymer around the vesicle membrane and leading to vesicle scission (PubMed:17636067, PubMed:34744632, PubMed:36445308). Plays a role in organization of the actin cytoskeleton by mediating arrangement of stress fibers and actin bundles in podocytes (By similarity). During organization of the actin cytoskeleton, self-assembles into ring-like structure that directly bundles actin filaments to form typical membrane tubules decorated with dynamin spiral polymers (By similarity). Self-assembly increases GTPase activity and the GTP hydrolysis causes the rapid depolymerization of dynamin spiral polymers, and results in dispersion of actin bundles (By similarity). Remodels, through its interaction with CTTN, bundled actin filaments in a GTPase-dependent manner and plays a role in orchestrating the global actomyosin cytoskeleton (PubMed:19605363). The interaction with CTTN stabilizes the interaction of DNM2 and actin filaments and stimulates the intrinsic GTPase activity that results in actin filament-barbed ends and increases the sensitivity of filaments in bundles to the actin depolymerizing factor, CFL1 (By similarity). Plays a role in the autophagy process, by participating in the formation of ATG9A vesicles destined for the autophagosomes through its interaction with SNX18 (PubMed:29437695), by mediating recycling endosome scission leading to autophagosome release through MAP1LC3B interaction (PubMed:29437695, PubMed:32315611). Also regulates maturation of apoptotic cell corpse-containing phagosomes by recruiting PIK3C3 to the phagosome membrane (By similarity). Also plays a role in cytokinesis (By similarity). May participate in centrosome cohesion through its interaction with TUBG1 (By similarity). Plays a role in the regulation of neuron morphology, axon growth and formation of neuronal growth cones (By similarity). Involved in membrane tubulation (PubMed:24135484)

Primary Disease Associations & Inheritance

Centronuclear myopathy 1MIM #160150
AD
Charcot-Marie-Tooth disease, axonal type 2MMIM #606482
AD
Charcot-Marie-Tooth disease, dominant intermediate BMIM #606482
AD
Lethal congenital contracture syndrome 5MIM #615368
AR
UniProtMyopathy, centronuclear, 1
1431
ClinVar variants
4
Pathogenic / LP
1.00
pLI score· haploinsufficient
0
Active trials
Clinical SummaryDNM2
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
4 Pathogenic / Likely Pathogenic· 251 VUS of 1431 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.18LOEUF
pLI 1.000
Z-score 5.66
OE 0.07 (0.030.18)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
3.48Z-score
OE missense 0.57 (0.520.63)
302 obs / 527.0 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.07 (0.030.18)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.57 (0.520.63)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.18
01.21.6
LoF obs/exp: 3 / 43.1Missense obs/exp: 302 / 527.0Syn Z: -2.09

ClinVar Variant Classifications

1431 submitted variants in ClinVar

Classification Summary

Pathogenic3
Likely Pathogenic1
VUS251
Likely Benign200
Benign3
Conflicting4
3
Pathogenic
1
Likely Pathogenic
251
VUS
200
Likely Benign
3
Benign
4
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
3
0
3
Likely Pathogenic
0
1
0
0
1
VUS
14
208
26
3
251
Likely Benign
0
1
102
97
200
Benign
0
0
3
0
3
Conflicting
4
Total14210134100462

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

DNM2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

DYNAMIN 2; DNM2
MIM #602378 · *

Centronuclear myopathy 1

MIM #160150

Molecular basis of disorder known

Autosomal dominant

Charcot-Marie-Tooth disease, axonal type 2M

MIM #606482

Molecular basis of disorder known

Autosomal dominant

Charcot-Marie-Tooth disease, dominant intermediate B

MIM #606482

Molecular basis of disorder known

Autosomal dominant

Lethal congenital contracture syndrome 5

MIM #615368

Molecular basis of disorder known

Autosomal recessive
Clinical Literature
Landmark / reviewRecent case evidence
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
A novel DNM2 variant associated with centronuclear myopathy: a case report.
Rimoldi M et al.·Front Genet
2025🔓 Open AccessCase report
BIN1 reduction ameliorates DNM2-related Charcot-Marie-Tooth neuropathy.
Goret M et al.·Proc Natl Acad Sci U S A
2025🔓 Open Access
DNM2 levels normalization improves muscle phenotypes of a novel mouse model for moderate centronuclear myopathy.
de Carvalho Neves J et al.·Mol Ther Nucleic Acids
2023🔓 Open AccessFunctional

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →